Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0CK3C
|
||||
| Former ID |
DIB005988
|
||||
| Drug Name |
Ulodesine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Autoimmune diabetes [ICD10:E08-E13] | Phase 2 | [523572] | ||
| Company |
BioCryst Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C12H16N4O3
|
||||
| Canonical SMILES |
OC[C@H]1CN(Cc2c[nH]c3C(=O)NC=Nc23)C[C@@H]1O
|
||||
| InChI |
1S/C12H16N4O3/c17-5-8-3-16(4-9(8)18)2-7-1-13-11-10(7)14-6-15-12(11)19/h1,6,8-9,13,17-18H,2-5H2,(H,14,15,19)/t8-,9+/m1/s1
|
||||
| InChIKey |
AFNHHLILYQEHKK-BDAKNGLRSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Purine nucleoside phosphorylase | Target Info | Inhibitor | [1572591] | |
| BioCyc Pathway | Arsenate detoxification I (glutaredoxin) | ||||
| Purine nucleotides degradation | |||||
| Urate biosynthesis/inosine 5'-phosphate degradation | |||||
| Purine deoxyribonucleosides degradation | |||||
| Purine ribonucleosides degradation to ribose-1-phosphate | |||||
| Guanosine nucleotides degradation | |||||
| Adenosine nucleotides degradation | |||||
| Superpathway of purine nucleotide salvage | |||||
| Adenine and adenosine salvage III | |||||
| Guanine and guanosine salvage | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| EGFR1 Signaling Pathway | |||||
| PathWhiz Pathway | Purine Metabolism | ||||
| Nicotinate and Nicotinamide Metabolism | |||||
| Reactome | Purine salvage | ||||
| Purine catabolism | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.